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Abstract
Purpose EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine 
therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance 
of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine 
therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET + C).
Methods A total of 3746 women were included in this joint analysis. 2630 patients received 5 years of ET alone (ABCSG-
6/8, TransATAC) and 1116 patients received ET + C (GEICAM 2003-02/9906). The primary objective was to evaluate the 
ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone 
and ET + C. Cox proportional hazard models were used for these analyses.
Results EPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49–3.13), P < 0.0001) as well 
as in those who received ET + C (HR 2.27 (1.99–2.59), P < 0.0001). Women who received ET + C had significantly smaller 
increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin = 5; 12% ET + C vs. 
20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-interaction = 0.022).
Conclusions In this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly 
reduced in women who received ET + C versus ET alone. Our indirect comparisons suggest that a high EPclin score can 
predict chemotherapy benefit in women with ER-positive, HER2-negative disease.
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Introduction
For the clinical management of patients with oestrogen 
receptor (ER)-positive breast cancer, several clinico-path-
ological and molecular characteristics of the tumour have 
to be considered for prognosis and treatment decisions. 
Almost all women with ER-positive, HER2-negative breast 
cancer will receive at least 5 years of endocrine therapy but 
the question who will benefit from adjuvant chemotherapy 
is more challenging. Comparisons of different adjuvant 
polychemotherapy regimens have shown that breast cancer 
mortality can be reduced by about one-third, but this reduc-
tion depends on absolute risks without chemotherapy and 
proportional reductions were largely independent by clin-
ico-pathological parameters [1]. Over the last two decades 
several multigene tests have been developed to aid the selec-
tion of patients for whom adjuvant chemotherapy might be 
appropriate based on prognosis [2, 3]. All of these tests pre-
dict the likelihood of disease recurrence or progression [2, 
4–7], and some have shown to predict relative benefit from 
chemotherapy [8, 9]. However, none of the multigene tests 
have so far shown that they can aid in the decision-making 
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process regarding which chemotherapy regime to use [10, 
11].
The EndoPredict test combines the expression of three 
proliferative and five ER-signalling-associated genes 
together with four normalisation and control genes and can 
be measured in formalin-fixed, paraffin-embedded tissue 
sections by quantitative real-time polymerase chain reac-
tion (qRT-PCR) in decentralised laboratories [12]. EPclin 
incorporates information on nodal status and tumour size 
and is used as the diagnostic algorithm in the clinical setting. 
EPclin has been validated as a prognostic test in pre- and 
postmenopausal women with ER-positive, HER2-negative 
breast cancer [6, 11, 13, 14]. EPclin was highly prognostic 
and identified a large proportion of women as low risk with 
a less than ten percent 10-year risk of distant recurrence 
[6, 14]. In the TransATAC cohort, the two signatures that 
include clinicopathological parameters, EPclin and Pros-
igna, were substantially more prognostic and had a superior 
risk stratification when compared to immunohistochemical 
markers, Oncotype Dx Recurrence score, or Breast Cancer 
Index, particularly in women with lymph node-positive dis-
ease who are most likely to receive chemotherapy [2]. In the 
GEICAM/9906 trial, EPclin identified a group of patients 
with node-positive disease who had a particularly low risk 
of distant recurrence and an absolute risk reduction of 30% 
compared to patients with high-risk disease [15].
Retrospective and prospective clinical trials looking at 
chemotherapy prediction using multigene tests in women 
with lymph node-negative or node-positive disease have 
reported their results [8, 9, 16, 17]. Oncotype Dx Recur-
rence score was shown to predict chemotherapy benefit, 
mostly in women with a high score (≥ 31); however, patients 
with HER2-positive disease and samples from the training 
cohort were included [9, 17]. In a more recent report from 
the prospective TAILORx study [16], patients with ER-pos-
itive, HER2-negative disease and a mid-range Oncotype Dx 
Recurrence score (11–25) did not have any chemotherapy 
benefit, and no significant interaction with treatment was 
observed [16]. Of note, results showed that women aged 
50 years or younger with an intermediate Oncotype Dx risk 
score had a potential benefit from adjuvant chemotherapy. 
The MINDACT trial reported that women with a clinical 
high risk and molecular low risk had an excellent distant-
recurrence risk after 5 years [8]. However, they were not able 
to address the question of chemotherapy benefit due to low 
power and low event rates.
Despite the prognostic ability of EPclin, it has not yet 
been shown whether it can predict chemotherapy benefit. 
Archival samples from previous randomised trials of endo-
crine therapy (ET) with or without chemotherapy (C) in 
patients with ER-positive, HER2-negative tumours have 
largely been exhausted. In addition, a prospective trial with-
holding chemotherapy from high-risk patients would be 
unethical. We therefore used an alternative study design to 
evaluate the ability of EPclin to predict adjuvant chemother-
apy benefit for patients with ER-positive, HER2-negative 
disease. Here, we investigate in a non-randomised setting 
whether EPclin can predict chemotherapy benefit in pre- 
and postmenopausal women with early stage ER-positive, 
HER2-negative disease, who had received 5 years of endo-
crine therapy alone or in combination with chemotherapy.
Methods
In this retrospective, comparative analysis, the EPclin was 
investigated in pre- and postmenopausal women with ER-
positive, HER2-negative breast cancer treated with ET 
alone or ET + C using data from five large clinical trials. 
All patients from the GEICAM/9906 (N = 500) and GEI-
CAM 2003/02 (N = 616) trials received ET + C. All patients 
from the ABCSG-6 (N = 378), ABCSG-8 (N = 1324), and 
TransATAC (N = 928) trials received five years of ET only, 
and served as our comparison group. The original ABCSG-6 
trial included 2020 postmenopausal women with hormone 
receptor-positive breast cancer who received 5 years of 
tamoxifen alone or 5 years of tamoxifen plus aminoglu-
tethimide for the first 2 years [18]. The ABCSG-8 trial 
randomised 3714 postmenopausal women with hormone 
receptor-positive breast cancer to 5 years of tamoxifen or 
2 years of anastrozole followed by 3 years of tamoxifen [19]. 
Women in the TransATAC trial were postmenopausal and 
received 5 years of tamoxifen or anastrozole alone [20]. The 
GEICAM/9906 trial randomised pre- and postmenopausal 
women with lymph node-positive breast cancer to treatment 
with fluorouracil, epirubicin, and cyclophosphamide (FEC) 
or with FEC followed by weekly paclitaxel (FEC-P) [21]. 
Finally, the GEICAM 2002/03 trial entered pre- and post-
menopausal women with node-negative disease and com-
pared fluorouracil, doxorubicin, and cyclophosphamide 
(FAC) × 6 or FAC × 4 followed by wP × 8 (FAC-wP) [22].
The EPclin was developed in pre- and postmenopausal 
women with ER-positive, HER2-negative breast cancer 
[14]. For all five trials, EP molecular scores were gener-
ated by qRT-PCR gene analysis by Myriad Genetics, Inc. 
blinded to all clinical outcome data. The EP molecular score 
incorporates the expression of eight cancer-related genes 
(BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP, 
and STC2), three housekeeping genes (CALM2, OAZ1, and 
RPL37A), and one control gene (HBB). The EPclin incor-
porates nodal status and tumour size into the molecular 
score. Higher EPclin scores indicate a higher risk of distant 
recurrence. Predefined cut-off points were used to determine 
low- and high-risk patients (EPclin low risk < 3.3, EPclin 
high risk ≥ 3.3).
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Statistical analysis
The primary endpoint was distant recurrence-free inter-
val (DRFI), defined as the time from randomisation in the 
primary study to distant recurrence of breast cancer. Local 
recurrence, regional recurrence, and contralateral second 
primary or secondary breast cancer in the ipsilateral breast 
were not considered as distant recurrence. Documented 
deaths due to breast cancer without distant recurrence 
occurring prior to death were also considered as a distant 
recurrence at the time of death. The secondary endpoint 
was breast cancer-free interval (BCFI), defined as the time 
from randomisation in the primary study to recurrence of 
any breast cancer (including local, regional, or distant recur-
rence or contralateral second primary or secondary breast 
cancer). Documented deaths due to breast cancer without 
recurrence of breast cancer or contralateral second primary 
breast cancer prior to the death were also considered as a 
recurrence of breast cancer at the time of death. All analyses 
were censored at 10 years of follow-up.
The primary objective of this analysis was to generate 
risk curves estimating 10-year DR as a continuous function 
of EPclin score separately for patients who received adjuvant 
ET + C and those who received ET only. Secondary objec-
tives included (i) prognostic ability of EPclin for DRFI in 
ET + C and ET alone, (ii) prognostic ability of EPclin for 
BCFI in ET + C and ET alone, (iii) magnitude of benefit of 
ET + C compared to ET alone for DRFI and BCFI based on 
EPclin score, and (iv) as above but investigating EP molecu-
lar score. The primary analysis population were pre- and 
postmenopausal women with ER-positive, HER2-negative 
breast cancer who received five years of ET + C or ET alone. 
A predefined statistical analysis plan was approved by all 
research groups prior to data merge and data analyses. IS 
(TransATAC), DH (ABCSG), Lidija Soelkner (ABCSG), 
and Jesus Herranz Valera (GEICAM) had full access to 
clinical data for all five trials and performed all statistical 
analyses. We assessed 10-year distant recurrence risk using 
Cox proportional hazard models for a series of EPclin scores 
for ET alone and ET + C separately. To compare the prog-
nostic performance of the continuous EPclin and EP scores, 
hazard ratios (HRs) and associated 95% confidence intervals 
(CIs) were estimated from Cox proportional hazards regres-
sion models. All HRs are for a one unit change in EPclin 
score. Multivariable models were adjusted for nodal status 
(0, 1–3, 4–10 and 10 + positive nodes), tumour size (T1a/b, 
T1c, T2 and T3), and tumour grade. A test for interaction 
was performed using Cox models containing chemotherapy 
treatment and EPclin score as a continuous variable. All 
statistical analyses were two-sided, and a P value of less 
than 0.05 was regarded as significant. All analyses were 
performed with Stata (version 13.1; StataCorp), R (version 
3.3.2), and SAS software (version 9.4).
Results
A total of 3746 pre- and postmenopausal women with 
ER-positive, HER2-negative breast cancer who received 
5 years of ET and for whom EPclin was measured were 
included in this analysis. Table 1 shows baseline demo-
graphics by treatment group (ET alone vs. ET + C). In 
brief, 2630 women (70.2%) who received ET alone were 
all postmenopausal, significantly older, had significantly 
smaller tumours, significantly more node-negative disease, 
and significantly fewer poorly differentiated tumours (all 
P < 0.05) compared to those 1116 pre- and postmenopau-
sal women who received ET + C (Table 1). 51% of patients 
who received ET + C were premenopausal. Women on 
ET alone had a significantly lower median EPclin score 
than those who received ET + C (3.07 vs. 3.67; P < 0.001) 
(Table 1, Supplemental Fig. 1).
Women receiving ET alone had a median follow-up 
time of 9.6 years (IQR 6–10). A total of 279 DR events 
(11%) were recorded for these women over a 10-year fol-
low-up period, and 120 (6%; 120/2202) late DR events 
(years 5–10). Median time to DR for women on ET + C 
was 9 years (IQR 7–10) with a total of 146 (13%) DR 
events recorded, with 53 (5%; 53/1008) late DR events. 
Number of events and time to events are presented Table 1.
Distant recurrence‑free interval
Figure 1 shows the relationship between EPclin scores and 
10-year DR (%) for ET alone and ET + C. Women receiv-
ing ET alone had larger 10-year DR risks with increasing 
EPclin scores compared to those on ET + C (Table 2). For 
example, women on ET alone with an EPclin score of 5 
had a 10-year DR risk of 46% compared to 26% for women 
who received ET + C, which translates to an absolute risk 
difference of 20%. In contrast, no differences in 10-year 
DR risks were observed for small EPclin scores, i.e. those 
who are at low risk of recurrence (Fig. 1, Table 2). We per-
formed a sensitivity analysis excluding all premenopausal 
women and observed very similar results (EPclin score 
5: 46% vs. 28% 10-year distant recurrence risk). To test 
the statistical strength between chemotherapy benefit and 
EPclin, an interaction test between EPclin as a continuous 
variable and treatment (ET vs. ET + C) was statistically 
significant (P = 0.022).
The molecular EP was separately investigated in both 
treatment groups. A separation of the 10-year DR risk 
curves between ET alone versus ET + C was observed with 
increasing EP scores but the difference was statistically not 
significant (Fig. 2), which was reflected with a non-signifi-
cant interaction between treatment and EP score (P = 0.17) 
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and overlapping 95% confidence intervals (Fig. 2). Still, 
EP was prognostic for DR in the ET alone group (HR 
1.28 (1.23–1.34), P < 0.0001) and ET + C group (HR 1.22 
(1.15–1.29), P < 0.0001), but these HRs are not directly 
comparable to those presented above for EPclin.
EPclin was highly prognostic in women who received ET 
alone (HR 2.79 (2.49–3.13), P < 0.0001) as well as in those 
who received ET + C (HR 2.27 (1.99–2.59), P < 0.0001) in 
a univariate analysis (Fig. 3). We furthermore investigated 
EPclin in two distinct follow-up periods; early (0–5 years) 
and late (5–10 years). EPclin was more prognostic in women 
who received ET alone compared to those on ET + C in both 
follow-up periods (Fig. 3). In women who received ET alone, 
EPclin was non-significantly more prognostic for late distant 
recurrence than for early distant recurrence (0–5 years: HR 
2.76 vs. 5–10 years: HR 2.85; (Fig. 3)). In contrast, EPc-
lin was non-significantly more prognostic for early distant 
recurrence in women who received ET + C (0–5 years: HR 
2.49 vs. 5–10 years: HR 1.86). When adjusted for clinical 
parameters, EPclin remained highly prognostic in both treat-
ment groups (data not shown).
Breast cancer‑free interval
Our secondary endpoint was BCFI, and we observed simi-
lar results. 10-year BC risks were significantly higher 
in women on ET alone with the increasing EPclin score 
(Fig. 4). Women on ET alone with an EPclin score of 5 
had a 10-year recurrence risk of 57% compared to 29% for 
women who received ET + C. We observed a significant 
interaction between EPclin and treatment for any recur-
rence (P = 0.025). EPclin was highly prognostic for BC in 
women on ET alone (HR 2.50 (2.26–2.76), P < 0.0001) as 
well as in those who received ET + C (HR 2.06 (1.82–2.34), 
P < 0.0001). The prognostic value of EPclin remained sig-
nificant after adjustments for clinical parameters. Finally, 
the EP molecular score was investigated for any recurrence, 
but no significant differences between EP scores and 10-year 
Table 1  Patient demographics 
according to treatment group 
(ET alone vs. ET + C)
ET endocrine therapy, ET + C endocrine therapy plus chemotherapy, IQR interquartile range, DR distant 
recurrence, DRFI distant recurrence-free interval, BCFI breast cancer-free interval
ET only (N = 2630) ET + C (N = 1116) All (N = 3746)
Age (years), median (IQR) 63.7 (58.0–70.7) 51.0 (44.0–59.0) 61.00 (54.0–68.0)
Menopausal status
 Premenopausal – 572 (51.3%) 572 (15.3%)
 Postmenopausal 2630 (100.0%) 544 (48.8%) 3174 (84.7%)
Tumour stage
 T1a/b 422 (16.1%) 84 (7.5%) 506 (13.5%)
 T1c 1333 (50.7%) 508 (45.5%) 1841 (49.2%)
 T2 829 (31.5%) 487 (43.6%) 1316 (35.1%)
 T3 43 (1.6%) 37 (3.3%) 80 (2.14%)
 Unknown 3 (.1%) – 3 (.08%)
Nodal status
 Negative 1846 (70.2%) 616 (55.2%) 2462 (65.7%)
 1–3 positive 651 (24.8%) 326 (29.2%) 977 (26.1%)
 4–10 positive 111 (4.2%) 139 (12.5%) 250 (6.7%)
 10+ positive 22 (.8%) 35 (3.1%) 57 (1.5%)
Tumour grade
 Well 615 (23.4%) 131 (11.7%) 746 (19.9%)
 Intermediate 1683 (64.0%) 605 (54.2%) 2288 (61.1%)
 Poor 212 (8.1%) 322 (28.9%) 534 (14.3%)
 Undetermined 120 (4.6%) 58 (5.2%) 178 (4.8%)
 EP, median (IQR) 5.17 (3.88–6.77) 6.54 (4.81–8.66) 5.50 (4.11–7.36)
 EPclin, median (IQR) 3.07 (2.54–3.67) 3.67 (3.05–4.45) 3.23 (2.66–3.94)
 DR (0–10 years) 279 (10.6%) 146 (13.1%) 425 (11.4%)
 Any recurrence (0–10 years) 398 (15.1%) 171 (15.3%) 569 (15.2%)
 DR (5–10 years) 120/2202 (5.5%) 53/1008 (5.3%) 173/3210 (5.4%)
 Any recurrence (5–10 years) 182/2155 (8.5%) 66/997 (6.6%) 248/3152 (7.9%)
 Time to DRFI (years), median (IQR) 9.60 (5.97–10.00) 9.19 (7.47–10.00) 9.44 (6.75–10.00)
 Time to BCFI (years), median (IQR) 9.38 (5.53–10.00) 9.12 (7.34–10.00) 9.29 (6.37–10.00)
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risks were observed (data not shown). A test for interac-
tion was not significant between continuous EP score and 
treatment (P = 0.18). However, EP was significantly prog-
nostic for any recurrence in women on ET alone (HR 1.25 
(1.20–1.30), P < 0.0001) and those on ET + C (HR 1.19 
(1.13–1.26), P < 0.0001).
Discussion
Multigene tests are increasingly used for the prognostic 
evaluation of ER-positive, HER2-negative breast cancer 
and for the selection of patients for adjuvant chemotherapy. 
EPclin is highly prognostic in women with node-negative 
and node-positive disease [6, 11, 13, 14, 22]. Herein, we 
investigated the value of EPclin in women treated with 
endocrine therapy alone and those who received endocrine 
therapy plus chemotherapy. Patients with a high EPclin score 
(e.g. those considered high risk by EPclin) who received 
chemotherapy had a significantly lower 10-year distant 
recurrence risk than those who received endocrine therapy 
alone. Importantly, no differences in 10-year distant recur-
rence risks were observed between the two treatment groups 
for low EPclin scores (< 3.3). A significant test for interac-
tion was observed, further emphasising the potential benefit 
of adding chemotherapy to those with high EPclin scores. 
Although our results were generated from a non-randomised, 
retrospective analysis, they are consistent with other studies 
Fig. 1  Likelihood of distant 
recurrence (DR) as a continu-
ous function of EPclin for ET 
alone (black) and ET + C (grey) 
(dotted lines = 95% confidence 
intervals)
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Table 2  10-year risk (%) with 
95% confidence intervals 
and absolute risk differences 
for distant recurrence for 
endocrine-treated patients alone 
(ET alone) and endocrine plus 
chemotherapy-treated patients 
(ET + C) according to EPclin 
score
ET endocrine therapy, ET + C endocrine therapy plus chemotherapy, EPclin endopredict clinical
EPclin score ET alone ET + C Absolute risk difference 
between ET alone and 
ET + C
1 1.0% (0.6–1.4) 1.1% (0.5–1.7) − 0.1%
2 2.8% (2.1–3.5) 2.5% (1.5–3.5) .3%
3 7.6% (6.4–8.8) 5.7% (4.1–7.2) 1.9%
4 19.8% (17.6–22.0) 12.4% (10.1–14.6) 7.4%
5 46.1% (40.2–51.4) 25.8% (22.0–29.5) 20.3%
6 82.2% (72.1–88.6) 49.2% (40.5–56.7) 33.0%
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that demonstrate chemotherapy benefit for patients with 
high-risk disease based upon molecular analyses [8, 9, 16]. 
The current analysis approach can facilitate insight into the 
predictive value of EPclin for women with ER-positive, 
HER2-negative breast cancer. Our results furthermore sug-
gest that some women with a low EPclin score, but clinically 
Fig. 2  Likelihood of distant 
recurrence (DR) as a continu-
ous function of EP for ET alone 
(black) and ET + C (grey) 
(dotted lines = 95% confidence 
intervals)
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Fig. 3  Univariable hazard ratios 
(95% CI) for the prognostic 
value of EPclin for DR accord-
ing to treatment group and 
follow-up period
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high-risk tumours, received unnecessary chemotherapy. In 
addition, women with high EPclin scores who only received 
endocrine therapy alone would have been good candidates 
for adjuvant chemotherapy.
An initial report on the predictive value of Oncotype Dx 
Recurrence score showed the magnitude of chemotherapy 
benefit [9]. However, a proportion of women included in the 
study were also part of the discovery cohort for the Oncotype 
Dx Recurrence score, and some had HER2-positive disease. 
More recently, the TAILORx [16] trial reported that women 
with ER-positive, node-negative disease did not derive any 
chemotherapy benefit if they had a mid-range Oncotype Dx 
Recurrence score (< 25), indicating that only those catego-
rised as high risk of developing a recurrence benefit from 
adjuvant chemotherapy. Our analysis of EPclin showed simi-
lar results as patients with a 10-year risk below 10% showed 
no substantial benefit from chemotherapy while those above 
10% risk showed a chemotherapy benefit.
Most multigene prognostic test, including Oncotype Dx 
Recurrence score, Mammprint, Prosigna PAM50, are heavily 
weighted toward proliferation-related genes. The association 
of proliferation with response to chemotherapy varies based 
on the subgroup and is more prominent in higher prolifera-
tive subgroups (e.g. basal-like more than luminal A). Within 
each PAM50 subgroup, higher proliferative tumours were 
more likely to achieve complete pathological response [23]. 
In the neoadjuvant setting, 90% of multigene signatures and 
over 95% of individual genes that were significantly asso-
ciated with response to chemotherapy can be attributed to 
proliferation [23]. EPclin incorporates proliferation-related 
genes, which might be one reason for our differential find-
ings between the two treatment groups. Furthermore, EPclin 
incorporates nodal status and tumour size, both of which are 
strong prognostic factors for recurrence and both are tradi-
tionally considered important factors when deciding about 
adjuvant chemotherapy treatment. Incorporation of clinico-
pathological factors allows a more accurate risk assessment 
than using a molecular signature alone [6]. Although in the 
Early Breast Cancer Trialists’ Collaborative Group overview 
[24] the relative benefit of polychemotherapy was similar 
in node-negative and node-positive breast cancer patients, 
and the absolute benefit of chemotherapy is much greater 
in women with node-positive disease, axillary lymph node 
involvement was not synonymous per se of a benefit from 
chemotherapy in patients with ER-positive, HER2-negative 
disease.
Strengths of our analysis include a large group of 
3746 pre- and postmenopausal women with ER-positive, 
Fig. 4  Likelihood of any 
recurrence (BC) as a continu-
ous function of EPclin for ET 
alone (black) and ET + C (grey) 
(dotted lines = 95% confidence 
intervals)
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HER2-negative breast cancer from large randomised clinical 
trials with long-term follow-up. Furthermore, we have clini-
cal outcome data for all patients and used well characterised 
tissue samples. EPclin for all trials was measured in the same 
laboratory, with all personnel being blinded to clinical out-
come data. We included patients who have been treated with 
modern chemotherapy regimens such as FEC/FAC with or 
without paclitaxel. Limitations include that we were unable 
to compare the predictive value of EPclin in a prospective, 
randomised trial design. We used an indirect approach inves-
tigating the value of EPclin in women from large clinical 
trials who received endocrine therapy alone and compared 
them to those who received endocrine therapy plus chemo-
therapy. We believe that this retrospective approach is an 
effective way to evaluate the clinical usefulness of EPclin 
as data from large prospective, randomised trials are not 
available due to ethical, time, and resource considerations. 
Furthermore, EPclin incorporates nodal status and tumour 
size into its molecular score and therefore largely accounts 
for the two differential patient cohorts with different baseline 
risks in our analysis. This might also be the reason why no 
significant differences in 10-year distant recurrence risk was 
observed between ET alone versus ET + C with increasing 
molecular EP score. Without accounting for tumour size 
and nodal status, the absolute recurrence risk at a specific 
molecular score value depends on the baseline risk, which 
is higher in patient with node-positive disease.
In summary, EPclin was highly prognostic in women with 
ER-positive, HER2-negative breast cancer who received 
endocrine therapy alone and in those who received chemo-
therapy plus endocrine therapy. The results highlight that 
many women with low EPclin scores were likely to have 
been “over-treated” with chemotherapy and that many 
women with high EPclin scores may not have received nec-
essary chemotherapy treatment. Overall, our analysis sug-
gests that women with high EPclin scores benefitted from 
chemotherapy compared to those with the same EPclin 
score but receiving endocrine therapy alone, irrespective 
of node-positivity of the disease. Although our approach 
was an indirect comparison of EPclin in chemotherapy plus 
endocrine therapy treated women versus endocrine therapy 
alone, we demonstrated that a high EPclin sore can predict 
chemotherapy benefit in women with ER-positive, HER2-
negative disease.
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